drugset / Trial / NCT02582489

Autologous Bone Marrow Aspirate Concentrate in Patients Undergoing Meniscectomy

NCT02582489

Active not recruiting 100 enrolled Rush University Medical Center
RandomizedParallel-groupDouble-blindPrevention

Summary

The proposed research study aims to evaluate the effects of autologous bone marrow aspirate concentrate (BMAC) on the development and progression of osteoarthritis (OA) in patients undergoing meniscectomy. This prospective, randomized, double-blind clinical trial will compare patient-reported outcomes, specifically IKDC scores between patients who receive BMAC post-meniscectomy and those who receive a saline control injection. The study will also compare physical examination, MRI, radiographs, and synovial fluid analysis. Our hypothesis is that those who receive the autologous BMAC injection after the procedure will have better outcomes than those who do not.

Timeline

Start
2017-12-22
Primary completion
2026-11-30
Completion
2026-12-31

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Bone Marrow Aspirate Concentrate Cell therapy Other

Indications